Circulating DNA in the neoadjuvant setting of early stage colon cancer.
Authors : Bregni G, Pretta A, Senti C, Acedo Reina E, Vandeputte C, Trevisi E, Gkolfakis P, Kehagias P, Deleporte A, Van Laethem JL, Vergauwe P, Van den Eynde M, Deboever G, Janssens J, Demolin G, Holbrechts S, Clausse M, De Grez T, Peeters M, DHondt L, Geboes K, Besse-Hammer T, Rothé F, Flamen P, Hendlisz A, Sclafani F Year : 2022 Journal : Acta Oncol
Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer.
Authors : Bregni G, Vandeputte C, Pretta A, Senti C, Trevisi E, Acedo Reina E, Kehagias P, Liberale G, Moretti L, Bali MA, Demetter P, Flamen P, Carrasco J, DHondt L, Geboes K, Gokburun Y, Peeters M, Van den Eynde M, Van Laethem JL, Vergauwe P, Chapot CA, Buyse M, Deleporte A, Hendlisz A, Sclafani F Year : 2021 Journal : Acta oncol (Stockholm)
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials.
Authors : Giunta EF, Bregni G, Pretta A, Deleporte A, Liberale G, Bali MA, Moretti L, Troiani T, Ciardiello F, Hendlisz A, Sclafani F Year : 2021 Journal : Cancer Treat Rev
State of the art and future directions in the systemic treatment of neuroendocrine neoplasms.
Authors : Jungels C, Deleporte A Year : 2021 Journal : Curr Opin Oncol
Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.
Authors : Deleporte A, Van den Eynde M, Forget F, Holbrechts S, Delaunoit T, Houbiers G, Kalantari HR, Laurent S, Vanderstraeten E, De Man M, Vergauwe P, Clausse M, Van Der Auwera J, DHondt L, Pierre P, Ghillemijn B, Covas A, Paesmans M, Ameye L, Awada A, Sclafani F, Hendlisz A Year : 2021 Journal : Cancer Med